UNASSIGNED: 455 Background: @entity2240 gained NICE approval in March 2009 as first line treatment for @entity1358 ( @entity1358 ) and UK experience of use of @entity2240 is growing. The @entity5 ( @entity5 ) was the first @entity5 network in the UK to approve the use of @entity2240 in July 2007 and has the longest UK experience with this drug. The clinical outcomes of the @entity5 @entity1 are presented. METHODS: Data was collected and analysed regarding all @entity1 started on @entity2240 from 01/07/2007 to 30/09/2010. Follow up extended to 28/02/2011. Previously published predictors of response were compared to the @entity5 data to check applicability in this population. RESULTS: 129 @entity1 were identified with a median age of 63 years (range 21-87), 67% were male and WHO performance status was 0, 1 or 2 (33%, 51%, 16%). 80% of @entity1 had nephrectomy (60% radical) and 22% had prior systemic treatment. Median PFS was 10 months (range 0.25-27). Median @entity3012 (from @entity2240 initiation) was 17 months (range 0.25 - 47). Performance status was significantly associated with PFS and @entity3012 . The median number of treatment cycles was 5 (range 0.25-27). 64% of @entity1 were dose reduced and 9% had a schedule modification to minimise @entity137 . 21% of @entity1 had a delay of 4 weeks or more which was not detrimental to median PFS. Dose reduction at treatment initiation was associated with a significant decrease in @entity3012 . 11.6% of @entity1 required treatment for @entity1375 which was associated with a significant improvement in PFS and @entity3012 . 15.5% of @entity1 required treatment for @entity101 , which was associated with an improvement in @entity3012 , but not PFS. CONCLUSIONS: PFS in the @entity5 population is similar to trial data. Strategies to deal with side effects, including dose reduction (after treatment initiation), treatment delay and schedule changes, did not adversely affect PFS. Performance status 0, the development of new @entity101 or new @entity1375 can be regarded as markers of good prognosis in this population. Initial dose reduction should be avoided as this adversely affects prognosis.

U.K. experience of @entity2240 in the treatment of XXXX : Predictors of response from clinical practice.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1375 :: ('MESH:D007037', 'Disease') :: ['hypothyroidism'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity2240 :: ('MESH:C473478', 'Chemical') :: ['Sunitinib'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['NECN', 'cancer', 'North of England Cancer Network'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['mRCC', 'metastatic renal cell carcinoma']
@entity1358 :: (MESH:D002292,Disease) :: ['metastatic renal cell carcinoma']
